Aliases & Classifications for Progesterone Resistance

Aliases & Descriptions for Progesterone Resistance:

Name: Progesterone Resistance 54 29 13 52 69

Characteristics:

HPO:

32
progesterone resistance:
Inheritance autosomal recessive inheritance


External Ids:

OMIM 54 264080

Summaries for Progesterone Resistance

OMIM : 54 Progesterone prepares the endometrium for blastocyst implantation and allows maintenance of pregnancy. The major... (264080) more...

MalaCards based summary : Progesterone Resistance is related to bartholin's gland benign neoplasm and cardiovascular organ benign neoplasm, and has symptoms including abnormality of metabolism/homeostasis and female infertility. An important gene associated with Progesterone Resistance is PGR (Progesterone Receptor), and among its related pathways/superpathways are Glioma and Signaling by ERBB4. The drugs Progesterone and Hydroxocobalamin have been mentioned in the context of this disorder. Affiliated tissues include placenta, uterus and breast, and related phenotypes are behavior/neurological and integument

Related Diseases for Progesterone Resistance

Diseases related to Progesterone Resistance via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 104)
id Related Disease Score Top Affiliating Genes
1 bartholin's gland benign neoplasm 10.2 ESR1 PGR
2 cardiovascular organ benign neoplasm 10.2 ESR1 PGR
3 appendix leiomyoma 10.2 ESR1 PGR
4 bronchus adenoma 10.2 ESR1 PGR
5 glioma 10.2 ESR1 PGR
6 ovarian benign neoplasm 10.2 ESR1 PGR
7 plexiform neurofibroma 10.2 ESR1 PGR
8 paranasal sinus disease 10.2 ESR1 PGR
9 cervical lymphoepithelioma-like carcinoma 10.2 ESR1 PGR
10 histiocytic and dendritic cell cancer 10.2 ESR1 PGR
11 atypical lipomatous tumor 10.2 ESR1 PGR
12 pediatric intraocular retinoblastoma 10.2 ESR1 PGR
13 congenital disorder of glycosylation, type ic 10.2 ESR1 PGR
14 intestinal perforation 10.2 ESR1 PGR
15 perlman syndrome 10.2 ESR1 PGR
16 nervous system hibernoma 10.2 ESR1 PGR
17 bladder adenocarcinoma 10.2 ESR1 PGR
18 anal neuroendocrine tumor 10.2 ESR1 PGR
19 poliomyelitis 10.2 ESR1 PGR
20 vulva basal cell carcinoma 10.2 ESR1 PGR
21 villoglandular endometrial endometrioid adenocarcinoma 10.2 ESR1 PGR
22 vaginal adenosarcoma 10.2 ESR1 PGR
23 intraneural perineurioma 10.2 ESR1 PGR
24 middle ear adenocarcinoma 10.2 ESR1 PGR
25 paraphimosis 10.2 ESR1 PGR
26 central nervous system mature teratoma 10.2 ESR1 PGR
27 rectal neoplasm 10.2 ESR1 PGR
28 postpartum depression 10.2 ESR1 PGR
29 mucoepidermoid esophageal carcinoma 10.2 ESR1 PGR
30 combined t cell and b cell immunodeficiency 10.2 ESR1 PGR
31 anomalous left coronary artery from the pulmonary artery 10.2 ESR1 PGR
32 adult neuronal ceroid lipofuscinosis 10.2 ESR1 PGR
33 vulvar alveolar soft part sarcoma 10.2 ESR1 PGR
34 male reproductive organ benign neoplasm 10.2 ESR1 PGR
35 central nervous system primitive neuroectodermal neoplasm 10.2 ESR1 PGR
36 reactive arthritis 10.2 ESR2 PGR
37 ovarian clear cell malignant adenofibroma 10.2 ESR1 PGR
38 pilar sheath acanthoma 10.1 ESR1 PGR
39 polyembryoma of the ovary 10.1 ESR1 PGR
40 arthus reaction 10.1 ESR1 PGR
41 osteoblastoma 10.1 ESR1 PGR
42 fallopian tube carcinosarcoma 10.1 ESR1 PGR
43 ulceroglandular tularemia 10.1 ESR1 ESR2
44 anus adenocarcinoma 10.1 ESR1 PGR
45 endocervicitis 10.1 ESR2 PGR
46 esophagus sarcoma 10.1 ESR1 PGR
47 sclerosing hemangioma 10.1 ESR1 PGR
48 t-cell adult acute lymphocytic leukemia 10.1 ESR1 PGR
49 neuroschistosomiasis 10.1 ESR1 ESR2
50 retinal disease 10.1 ESR1 PGR

Graphical network of the top 20 diseases related to Progesterone Resistance:



Diseases related to Progesterone Resistance

Symptoms & Phenotypes for Progesterone Resistance

Symptoms by clinical synopsis from OMIM:

264080

Clinical features from OMIM:

264080

Human phenotypes related to Progesterone Resistance:

32
id Description HPO Frequency HPO Source Accession
1 abnormality of metabolism/homeostasis 32 HP:0001939
2 female infertility 32 HP:0008222

MGI Mouse Phenotypes related to Progesterone Resistance:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.8 ERRFI1 ESR1 ESR2 HSD17B2 PGR
2 integument MP:0010771 9.67 ERRFI1 ESR1 ESR2 PGR
3 limbs/digits/tail MP:0005371 9.62 ERRFI1 ESR1 ESR2 PGR
4 neoplasm MP:0002006 9.56 ERRFI1 ESR1 ESR2 PGR
5 no phenotypic analysis MP:0003012 9.46 ERRFI1 ESR1 ESR2 PGR
6 normal MP:0002873 9.26 ESR2 PGR ERRFI1 ESR1
7 renal/urinary system MP:0005367 8.92 ERRFI1 ESR1 ESR2 HSD17B2

Drugs & Therapeutics for Progesterone Resistance

Drugs for Progesterone Resistance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 183)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 57-83-0 5994
2
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 5460373 44475014
3
Benzocaine Approved Phase 4 1994-09-7, 94-09-7 2337
4
Alprostadil Approved, Investigational Phase 4 745-65-3 149351
5
Mifepristone Approved, Investigational Phase 4 84371-65-3 55245
6
Misoprostol Approved Phase 4 59122-46-2 5282381
7
Methyltestosterone Approved Phase 4,Phase 3,Early Phase 1 58-18-4 6010
8
Pioglitazone Approved, Investigational Phase 4,Early Phase 1 111025-46-8 4829
9
Testosterone Approved, Investigational Phase 4,Phase 3,Early Phase 1 58-22-0 6013
10
Leuprolide Approved, Investigational Phase 4 53714-56-0 3911 657181
11
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
12
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
13
leucovorin Approved, Nutraceutical Phase 4 58-05-9 54575, 6560146 143
14
Manganese Approved, Nutraceutical Phase 4 7439-96-5 27854
15 tannic acid Approved, Nutraceutical Phase 4
16 Hypoglycemic Agents Phase 4,Phase 2,Early Phase 1
17 insulin Phase 4,Phase 3,Phase 2,Phase 1
18 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2,Phase 1
19 Contraceptive Agents Phase 4,Phase 3,Phase 1,Phase 2
20 Hematinics Phase 4
21 Micronutrients Phase 4,Phase 3
22 Trace Elements Phase 4,Phase 3
23 Vitamin B 12 Phase 4
24 Vitamin B Complex Phase 4
25 Vitamins Phase 4,Phase 3
26
Daidzein Phase 4 486-66-8 5281708
27 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Phytoestrogens Phase 4
32 Antacids Phase 4
33 Anti-Ulcer Agents Phase 4
34 Contraceptives, Oral Phase 4,Phase 1,Phase 2
35 Contraceptives, Postcoital Phase 4
36 Gastrointestinal Agents Phase 4
37 Luteolytic Agents Phase 4
38 Oxytocics Phase 4
39 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 1,Early Phase 1
40 Fertility Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 Progestins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Testosterone 17 beta-cypionate Phase 4,Phase 3,Early Phase 1
43
Testosterone enanthate Phase 4,Phase 3,Early Phase 1 315-37-7 9416
44 Testosterone undecanoate Phase 4,Phase 3,Early Phase 1
45 2,4-thiazolidinedione Phase 4
46
Cobalamin Nutraceutical Phase 4 13408-78-1 6438156
47 Folate Nutraceutical Phase 4
48 Inositol Nutraceutical Phase 4
49
Methylcobalamin Experimental, Nutraceutical Phase 4 13422-55-4
50 Vitamin B12 Nutraceutical Phase 4

Interventional clinical trials:

(show top 50) (show all 54)
id Name Status NCT ID Phase
1 Myo-inositol Versus D-chiro-inositol in the Treatment of Polycystic Ovary Syndrome and Insulin Resistance: Evaluation of Clinical, Metabolic, Endocrine and Ultrasound Parameters Completed NCT01514942 Phase 4
2 Exercise and Phytoestrogens: Effect on Factors Predisposing to Cardiovascular Disease(CVD) in Postmenopausal Women Completed NCT01048606 Phase 4
3 Same-Day Mifepristone-Misoprostol Compared to Misoprostol Only for Surgical Abortion Cervical Preparation Completed NCT02412618 Phase 4
4 Role of Myo-inositol and D-chiro Inositol on the Ovaric and Metabolic Functions Completed NCT01626443 Phase 4
5 Polycystic Ovary Syndrome (PCOS) and Sleep Apnea Terminated NCT00203996 Phase 4
6 Comparison Between Letrozole and Urinary Purified FSH in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome. Completed NCT02304107 Phase 3
7 Extended Clomiphene Citrate Regimen in Women With Polycystic Ovary Syndrome Completed NCT02381184 Phase 2, Phase 3
8 The Effect of Vitamin D Supplementation Among Overweight Jordanian Women With Polycystic Ovary Syndrome (PCOS) Completed NCT02328404 Phase 3
9 Comparison Between Laparoscopic Ovarian Diathermy and Urinary Purified FSH in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome. Recruiting NCT02304536 Phase 3
10 Comparison Between Letrozole and Laparoscopic Ovarian Drilling in Women With Clomiphene Resistant Polycystic Ovarian Syndrome (PCOS) Recruiting NCT02305693 Phase 3
11 Effects of Interleukin-1 Beta on Low Testosterone Levels in Men With Obesity and Metabolic Syndrome Recruiting NCT02672592 Phase 3
12 Dose Effects of Hormone Therapy (Two Doses of Estradiol Associated to Progesterone) on Inflammatory Markers Terminated NCT00236301 Phase 3
13 Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC Completed NCT00134680 Phase 2
14 Neoadjuvant Letrozole in Treating Postmenopausal Women With Estrogen-Receptor Positive and/or Progesterone-Receptor Positive Stage II, Stage IIIA, or Stage IIIB Breast Cancer Completed NCT00084396 Phase 2
15 Cavitation Ultrasound in Treatment of Patients With PCOS Completed NCT01622257 Phase 2
16 Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen Completed NCT00118157 Phase 2
17 Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia Completed NCT01859312 Phase 2
18 Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study Completed NCT00229697 Phase 2
19 Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer Completed NCT00365599 Phase 2
20 Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer Recruiting NCT02049190 Phase 1, Phase 2
21 Study of the Effect of Chemotherapy With Cabazitaxel on Prostate Cancer Recruiting NCT02512458 Phase 2
22 Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy Active, not recruiting NCT00999804 Phase 2
23 A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients Active, not recruiting NCT01650194 Phase 2
24 Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors Active, not recruiting NCT01831076 Phase 2
25 "E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study" Active, not recruiting NCT02957630 Phase 1, Phase 2
26 Progesterone Supplementation for HIV-positive Pregnant Women on Anti-Retrovirals Not yet recruiting NCT02400021 Phase 2
27 Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy Terminated NCT00225758 Phase 2
28 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1
29 A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives Completed NCT01291004 Phase 1
30 Examination of Breast Cancer Cells of Pre-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant. Recruiting NCT02936206 Phase 1
31 Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance Active, not recruiting NCT01197170 Phase 1
32 Evaluation of Oral Lipid Ingestion in Relation to Ovarian Androgen Secretion in Polycystic Ovary Syndrome (PCOS) Terminated NCT01489319 Phase 1
33 Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Withdrawn NCT02567396 Phase 1
34 Effects of Metformin and Oral Hormonal Contraceptive in Adolescents With Polycystic Ovary Syndrome Unknown status NCT00988078
35 The Effect of Acupuncture on Insulin Sensitivity Polycystic Ovary Syndrome Unknown status NCT02026323
36 Meal Timing on Glucose and Hyperandrogenism in PCOS Women Unknown status NCT01711476
37 Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy Completed NCT01016665
38 Ovulation Induction in Clomiphene Citrate Resistant PCO Women Completed NCT02341703 Early Phase 1
39 Corpus Luteum and Uterine Artery Doppler With Serum P and CA125 in Threatened Abortion Completed NCT02420769
40 Ovulation Induction in Women With Clomiphene Citrate Resistant PCOS Completed NCT01909141 Early Phase 1
41 Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer Completed NCT01385280
42 PCOS Twin Study - Environmental Factors in the Development of Polycystic Ovary Syndrome, Phase 2 Completed NCT00444288
43 Effect of Ramadan Fasting on Ovulation and Insuline Resistance in Patients With PCOS Recruiting NCT02499289
44 Is There Association Between Vitamin D Levels And Insulin Resistance In Polycystic Ovary Syndrome? Recruiting NCT02803476
45 Option B+: Study on Safety, Viral Suppression, and Survival on Second Line ART Recruiting NCT02249962
46 Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer Therapy Recruiting NCT01957514
47 Ultrasound Characterization of Ovarian Follicle Dynamics in Women With Amenorrhea Recruiting NCT01927432
48 Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer Recruiting NCT03154190
49 Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer Recruiting NCT02158507
50 Triple Negative Breast Cancer: Identification Pilot Study of Predictive Transcriptome Profiles of Early Tumor Drug Resistance Observed in 18F-Fluorodeoxyglucose (FDG) PET Not yet recruiting NCT02850302

Search NIH Clinical Center for Progesterone Resistance

Genetic Tests for Progesterone Resistance

Genetic tests related to Progesterone Resistance:

id Genetic test Affiliating Genes
1 Progesterone Resistance 29

Anatomical Context for Progesterone Resistance

MalaCards organs/tissues related to Progesterone Resistance:

39
Placenta, Uterus, Breast

Publications for Progesterone Resistance

Articles related to Progesterone Resistance:

(show all 24)
id Title Authors Year
1
Progesterone resistance in endometriosis is modulated by the altered expression of microRNA-29c and FKBP4. ( 27778641 )
2016
2
Metformin targeting autophagy overcomes progesterone resistance in endometrial carcinoma. ( 27402506 )
2016
3
Human Endometrial Fibroblasts Derived from Mesenchymal Progenitors Inherit Progesterone Resistance and Acquire an Inflammatory Phenotype in the Endometrial Niche in Endometriosis. ( 27075616 )
2016
4
Upregulation of mitogen-inducible gene 6 triggers antitumor effect and attenuates progesterone resistance in endometrial carcinoma cells. ( 26450625 )
2015
5
Endometrial progesterone resistance and PCOS. ( 24405633 )
2014
6
Progesterone receptor isoforms A and B: new insights into the mechanism of progesterone resistance for the treatment of endometrial carcinoma. ( 24386010 )
2013
7
Mechanisms of endometrial progesterone resistance. ( 22085558 )
2012
8
Progesterone resistance in PCOS endometrium: a microarray analysis in clomiphene citrate-treated and artificial menstrual cycles. ( 21411543 )
2011
9
Subfertility linked to combined luteal insufficiency and uterine progesterone resistance. ( 20660062 )
2010
10
17Beta-hydroxysteroid dehydrogenase-2 deficiency and progesterone resistance in endometriosis. ( 20108182 )
2010
11
Altered gene expression profiling in endometrium: evidence for progesterone resistance. ( 20104428 )
2010
12
Progesterone resistance and endometrial disease. Preface. ( 20104423 )
2010
13
Progesterone resistance in a baboon model of endometriosis. ( 20104431 )
2010
14
Dioxin and endometrial progesterone resistance. ( 20104429 )
2010
15
Estrogen receptor-beta, estrogen receptor-alpha, and progesterone resistance in endometriosis. ( 20104427 )
2010
16
Revisiting reproduction: Prematurity and the puzzle of progesterone resistance. ( 20448578 )
2010
17
Endometriosis is associated with progesterone resistance in the baboon (Papio anubis) oviduct: evidence based on the localization of oviductal glycoprotein 1 (OVGP1). ( 18923157 )
2009
18
FKBP52 deficiency-conferred uterine progesterone resistance is genetic background and pregnancy stage specific. ( 17571166 )
2007
19
The altered distribution of the steroid hormone receptors and the chaperone immunophilin FKBP52 in a baboon model of endometriosis is associated with progesterone resistance during the window of uterine receptivity. ( 17636225 )
2007
20
Gene expression analysis of endometrium reveals progesterone resistance and candidate susceptibility genes in women with endometriosis. ( 17510236 )
2007
21
Progesterone resistance in endometriosis: link to failure to metabolize estradiol. ( 16406281 )
2006
22
Subfertility, uterine hypoplasia, and partial progesterone resistance in mice lacking the Kruppel-like factor 9/basic transcription element-binding protein-1 (Bteb1) gene. ( 15117941 )
2004
23
Progesterone resistance in women who have had breast cancer. ( 9532998 )
1998
24
Progesterone resistance. ( 3087144 )
1986

Variations for Progesterone Resistance

Expression for Progesterone Resistance

Search GEO for disease gene expression data for Progesterone Resistance.

Pathways for Progesterone Resistance

GO Terms for Progesterone Resistance

Biological processes related to Progesterone Resistance according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.32 ESR1 ESR2
2 lung alveolus development GO:0048286 9.26 ERRFI1 PGR
3 intracellular estrogen receptor signaling pathway GO:0030520 9.16 ESR1 ESR2
4 transcription initiation from RNA polymerase II promoter GO:0006367 9.13 ESR1 ESR2 PGR
5 steroid hormone mediated signaling pathway GO:0043401 8.8 ESR1 ESR2 PGR

Molecular functions related to Progesterone Resistance according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 sequence-specific DNA binding GO:0043565 9.67 ESR1 ESR2 PGR
2 enzyme binding GO:0019899 9.61 ESR1 ESR2 PGR
3 lipid binding GO:0008289 9.58 ESR1 ESR2 PGR
4 ATPase binding GO:0051117 9.48 ESR1 PGR
5 core promoter sequence-specific DNA binding GO:0001046 9.46 ESR1 ESR2
6 steroid hormone receptor activity GO:0003707 9.43 ESR1 ESR2 PGR
7 estrogen receptor activity GO:0030284 9.37 ESR1 ESR2
8 estrogen response element binding GO:0034056 9.32 ESR1 ESR2
9 RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding GO:0038052 9.16 ESR1 ESR2
10 RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding GO:0004879 9.13 ESR1 ESR2 PGR
11 steroid binding GO:0005496 8.8 ESR1 ESR2 PGR

Sources for Progesterone Resistance

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....